Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

Table 2 Rates and reasons for discontinuation

	Etanercept cohort	Adalimumab cohort	Tocilizumab cohort	Adalimumab versus etanercept^a	Tocilizumab versus etanercept^a	Tocilizumab versus adalimumab^a
	n = 419	n = 236	n = 74	OR (95% CI); p value	OR (95% CI); p value	OR (95% CI); p value
Discontinuations, n (%)	207 (49.4)	142 (60.4)	23 (31.1)	1.57 (1.03; 2.41); 0.037	0.20 (0.09; 0.45); <0.001	0.13 (0.06; 0.29); <0.001
Inefficacy, n (%)	50 (11.9)	52 (22.0)	9 (12.2)	1.65 (0.88; 3.08); 0.118	0.34 (0.11; 1.00); 0.050	0.20 (0.07; 0.60); 0.004
Remission, n (%)	54 (12.9)	22 (9.3)	2 (2.7)	0.78 (0.43; 1.40); 0.404	0.12 (0.02; 0.79); 0.027	0.16 (0.02; 1.05); 0.056
Intolerance, n (%)	15 (3.6)	15 (6.4)	2 (2.7)	2.28 (1.03; 5.04); 0.042	0.84 (0.18; 4.01); 0.826	0.37 (0.08; 1.79); 0.216
Details	Hypersensitivity (5), uveitis (3), vasculitis (1),	Infections (4)^b	Impetigo (1)
	Lymphoma (1)	Hypersensitivity (3)	Neutropenia (1)
	Elevated transaminases (1), neuro-psychiatric (4)^b	Pustulosis (1), neuro-psychiatric (5)^b		0.2	5
Others*, n (%)	88 (16.0)	53 (22.4)	10 (13.4)	1.21 (0.74; 1.96); 0.443	0.27 (0.10; 0.72); 0.009	0.22 (0.08; 0.60); 0.003

^aAnalyses weighted by an inverse probability of treatment estimated by a generalized propensity score. ^bInfections included pneumonia and soft tissue infections; Neuropsychiatric included headache, nausea, aggressiveness, anxiety, and vertigo. beta regression coefficient for continuous variables, CI confidence interval, OR odds ratio for categorical variable

ISSN: 1478-6362